"If you build it for the poor, the rich can come. If you build it for the rich, the poor can't come." -C.K. Prahalad F our billion people in the world live on ≈$5 a day or less, most in low-and middle-income countries (LMICs). 1 They face a host of economic and social hurdles, and noncommunicable diseases, such as cardiovascular diseases, are a growing component of those challenges. Over the last several decades, cardiovascular diseases have become responsible for a rising toll of death and disability among people in LMICs. 2 These conditions are now the leading cause of death in almost every region around the world. Furthermore, they may have a disparate impact on the economies of many LMICs, where they seem to preferentially affect working-age adults. In Brazil, approximately one third of deaths among people 35 to 64 years of age in coming years will be because of cardiovascular diseases as opposed to ≈10% in the United States. 3
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The reasons behind this rising worldwide epidemic in cardiovascular diseases are well established. An epidemiological transition has occurred during recent years in many large LMICs, such as China, India, and Brazil, which is closely linked to dramatic economic developments. 4 As malnutrition and infectious diseases decline, a large number of individuals in these countries are living longer and experiencing more chronic diseases traditionally associated with affluent societies, such as coronary heart disease, diabetes mellitus, obesity, and cancer. The impact of these diseases on LMICs has been further modified by their links to increasing tobacco use, air pollution, persistent poverty, and limited education. Tragically, the incidence and case fatalities for cardiovascular diseases in many of these regions are rising just as preventive measures and new therapies have curbed these diseases in Western countries. 5, 6 In this context, the article by Solla et al 7 published in this issue of Circulation: Cardiovascular Quality and Outcomes deserves special attention. These investigators report on their experiences by establishing an integrated regional network for poor patients with ST-segment-elevation myocardial infarction (STEMI) in the Salvador-Bahia region of Brazil who are treated by health centers within the public health system. Their principal findings, which report on patients admitted with STEMI between 2009 and 2010, highlight several challenges with efforts to expand the reach of specialized care in LMICs. First, the investigators describe considerable struggles with data collection, which seemed to be a key motivation for establishing their Regional STEMI Alert Team. Before 2009 and the start of their intervention, essentially no data existed on estimates of incidence, treatment, or outcomes of STEMI in this large region of Brazil.
After the intervention was started, however, the investigators noted almost immediately substantial gaps in care with delays in presentation and treatment. For example, the median time from symptom onset to admission was 180 minutes, which was much longer than the corresponding values in Western countries. Even more shocking was the length of time from admission to ECG of nearly 160 minutes. This delay by itself resulted in ≈8% of patients surpassing the window of eligibility for reperfusion therapy. Finally, of the 287 patients in whom STEMI was confirmed, only 119 (41.4%) were eligible for reperfusion therapy, and 90 (31.3%) received primary percutaneous coronary intervention or fibrinolytic therapy. Unfortunately, given the early nature of this program, data were unavailable on additional therapies or late outcomes. This is a key limitation to the current article. Such information will be collected, however, with the expanded Registro Soteropolitano de Infarto agudo domiocárdio com Supradesnivelamento do segment ST (RESISST) registry and hopefully provide additional insights. Understanding the use of low-cost therapies, such as aspirin and β-blockers, as well as long-term follow-up will be critical for evaluating the ultimate values of these programs for Brazil.
Despite its limitations, the article by Solla et al 7 is a positive step forward. It contributes to a growing body of literature on the treatment of STEMI patients in LMICs. Although numerous reports have been written on STEMI systems of care in the United States and Europe, 8, 9 these programs are often resource-intense and unrealistic to implement for most developing regions. In theory, however, integrated networks like this Brazilian program and others have the potential to transform care in LMICs by focusing on few affordable aspects of these systems, such as telecommunication advances and low-cost treatments. 10 Telemedicine services, for instance, played a critical part by automatically linking suspected STEMI patients with the Regional STEMI Alert Team experts. This
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January 2013 team was ultimately responsible for finding and confirming these diagnoses from a centralized location before activating a treatment plan that was individualized for the patient. The hope is that such a system could remain inexpensive, sustainable, and even scalable in LMICs. Lessons learned on efficiency in these regions also could have implications for Western countries where healthcare costs are skyrocketing. This type of reverse innovation has already made inroads with the introduction of low-cost, hand-held ECG and ultrasound devices in the United States that were originally produced for developing countries. 11 Of course, some may challenge the whole premise of value in these efforts. It could be argued, for example, that money spent on STEMI systems of care in LMICs might be better invested on primary cardiovascular risk prevention, vaccination programs for children, or even nonhealth-related societal needs. In my opinion, this is a false dichotomy created by the either-or fallacy: we either improve acute management of STEMI patients or we focus on another priority-but we cannot do both. Yet the truth is that for LMICs to meet the urgent needs of their changing populations, they will need to address many challenges simultaneously. Many therapies for STEMI patients (including fibrinolytic therapy) are cost-effective even in poor regions of the world. 12, 13 Emphasizing just 1 or 2 priorities for healthcare systems in LMICs is a limited approach that ignores a complex reality that the poor are not a monolith. They are made up of various segments and have societal needs that differ widely between those with low income and extreme poverty. 1 This approach also discounts the power of parallel efforts. A simple but novel example of this is the expansion of the role of ambulance services in one South Indian region from typical trauma and cardiac care to real-time disease surveillance for emerging infectious threats. 14 A little over a decade ago, Professor C.K. Prahalad from the University of Michigan posited a challenge to multinational corporations to shift their agenda toward better serving the world's poor-those vulnerable populations he identified at the Base (or Bottom) of the Pyramid. 15 Prahalad urged corporations to do this not just because it was the right thing to do but because it made good business sense. The enormous numbers of consumers and producers in this group would create new markets, he argued, if only given the chance. For STEMI care, the corresponding facts are clear: there are a growing number of STEMI patients in LMICs. These patients die at alarmingly high rates and frequently at young ages during their most productive working years. This situation occurs despite the availability of effective, low-cost treatments that can be applied in the acute setting. We need to shift our focus to better understanding opportunities for serving their needs not just because it is right but because it makes good policy sense.
